BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations

Cancer Research
Tomasz StoklosaTomasz Skorski

Abstract

BCR/ABL kinase-positive chronic myelogenous leukemia (CML) cells display genomic instability leading to point mutations in various genes including bcr/abl and p53, eventually causing resistance to imatinib and malignant progression of the disease. Mismatch repair (MMR) is responsible for detecting misincorporated nucleotides, resulting in excision repair before point mutations occur and/or induction of apoptosis to avoid propagation of cells carrying excessive DNA lesions. To assess MMR activity in CML, we used an in vivo assay using the plasmid substrate containing enhanced green fluorescent protein (EGFP) gene corrupted by T:G mismatch in the start codon; therefore, MMR restores EGFP expression. The efficacy of MMR was reduced approximately 2-fold in BCR/ABL-positive cell lines and CD34(+) CML cells compared with normal counterparts. MMR was also challenged by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), which generates O(6)-methylguanine and O(4)-methylthymine recognized by MMR system. Impaired MMR activity in leukemia cells was associated with better survival, accumulation of p53 but not of p73, and lack of activation of caspase 3 after MNNG treatment. In contrast, parental cells displayed accumulation of p53, p73, and acti...Continue Reading

Citations

Feb 14, 2012·Current Hematologic Malignancy Reports·Tomasz Skorski
Mar 20, 2012·Current Hematologic Malignancy Reports·N MuvarakF V Rassool
Jan 15, 2010·Current Opinion in Hematology·Paul La Rosée, Andreas Hochhaus
Mar 28, 2009·Pharmacological Reviews·Alexei Y BagrovOlga V Fedorova
Jul 2, 2010·The Journal of Clinical Investigation·Danilo PerrottiTomasz Skorski
Jul 3, 2009·Blood·Margret S FernandesMartin Sattler
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Aug 3, 2014·Seminars in Oncology Nursing·Debra Wujcik
Dec 8, 2010·Leukemia & Lymphoma·Sarah M Larson, Lucy A Godley
Aug 8, 2015·International Journal of Molecular Sciences·Ewelina SynowiecJanusz Błasiak
Apr 22, 2011·Critical Reviews in Oncology/hematology·José L SardinaAngel Hernández-Hernández
Sep 30, 2010·Seminars in Hematology·Paul La Rosée, Michael W Deininger
Nov 26, 2010·The Mount Sinai Journal of Medicine, New York·Stacey J Baker, E Premkumar Reddy
Jun 25, 2010·American Journal of Hematology·Vicent M GuillemJuan-Carlos Hernández-Boluda
Aug 5, 2011·Cancer Biology & Therapy·Moriya IwaizumiJohn M Carethers
Aug 7, 2013·Leukemia Research·Wei WangGuo-Qiang Lin
Jul 21, 2016·Cellular and Molecular Life Sciences : CMLS·Lorraine SpringuelJean-Christophe Renauld
Feb 6, 2017·Blood·Tessa L Holyoake, David Vetrie
Apr 24, 2013·Therapeutic Advances in Hematology·Raymond Lai, Robert J Ingham
Mar 1, 2012·Expert Review of Anticancer Therapy·Maria KarvelaTessa L Holyoake
Feb 15, 2020·International Journal of Molecular Sciences·Henning D PoppAlice Fabarius
Jan 8, 2020·Nature Reviews. Cancer·David VetrieMhairi Copland
Mar 13, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Fabrizio Condorelli, Armando A Genazzani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis